No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA vs DPP4i users.

For older patients with cancer and T2D, GLP-1 RA use is associated with lower all-cause mortality than DPP4i use.

In this article, you’ll find some of the top content that was published on LCGC this week, including an ASMS 2025 retrospective and an overview of microplastic research.